Form D · Biotechnology
Revel Pharmaceuticals Inc.
San Francisco, CA · CIK 0001800934
Offering snapshot reported Mar 23, 2022 · SEC filing
- Reported sold
- $5.75M Offering amount: $5.75M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 23, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 23, 2022 | Initial | $5,752,538 | No comparison | 3 | SEC filing |
| Apr 8, 2021 | Initial | $800,000 | No comparison | Not reported | SEC filing |
| Jan 23, 2020 | Initial | $533,333 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-438594
Series Seed-2 Preferred Stock and the common stock issuable upon conversion thereof.
Source: Form D, filed Mar 23, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patrick Burgermeister | Director |
| Jennifer Cochran | Director |
| Aaron James Cravens | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2325 3rd Street
San Francisco, CA, 94107
San Francisco, CA, 94107